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indicated as primary (n = 5) or secondary (n = 22; of which 4 are secondary 
and/or exploratory) or both (n = 12).The majority of PRO statements are characterized 
as sign and symptom measures followed by HRQOL measures. Within FDA, 5 
required PRO and 8 suggest use of PRO. The majority of PRO statements are 
characterized as sign and symptom measures, followed by measures of function/
feeling. CONCLUSIONS: PRO data in many disease areas are viewed by regulatory 
agencies as supportive evidence of the primary endpoint. PRO data are essential in 
the support of product submissions to regulatory stakeholders, especially within 
EMEA.
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OBJECTIVES: To facilitate international comparison of data, PRO translations must 
be conceptually equivalent to the original and culturally relevant to the target country. 
To assess the relevance of conducting a multi-step process on a PRO translation with 
the aim of using it on an immigrant population speaking that language in a different 
country, we investigated the presence and nature of differences between the 2 language 
versions thus obtained. METHODS: Three translations were compared before and 
after adaptation to the context of a host country: 1) the Turkish and German Turkish 
version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ); 2) the Indian 
Gujarati and UK Gujarati version of the Subject Self Report on Symptoms Worksheet 
(SSRSW); and 3) the Chinese Mandarin and US Mandarin version of the National 
Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25). RESULTS: Six of the 
eight items in the Turkish DTSQ were modiﬁed following cognitive debrieﬁng with 
Turkish speakers in Germany. The Turkish population in Germany tends to use more 
old-fashioned wording which doesn’t reﬂect the original language’s recent evolution. 
All four items in the Gujarati SSRSW needed changing when adapting it to a UK 
context. Some initially translated wording was reverted back to English, or substituted 
with transliterated English terms. In the Mandarin NEI-VFQ-25, out of 29 items, 11 
were modiﬁed when adapting it for the USA. The language used in the initial transla-
tion was considered too basic for the target population in the USA, which tends to 
have a higher level of education. CONCLUSIONS: Immigrant language is affected by 
the host country’s culture and language, and/or by separation from the mother 
country, and is no longer fully comparable with the language in the country of origin. 
Adaptation and cognitive debrieﬁng on immigrant populations in target countries is 
advisable to establish culturally relevant translations.
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OBJECTIVES: Country-speciﬁc social preference sets have been estimated to support 
the use of EQ-5D in computing QALYs for cost-utility analysis. However these value 
sets have limited applicability in non-economic applications since a) they incorporate 
the state “dead” which is irrelevant in many therapeutic settings, and(b) they are based 
on hypothetical preferences from 3rd parties who may not have any experience of 
speciﬁc EQ-5D health states. This paper reports on the construction of a scoring 
system for EQ-5D based on self-rated VAS values generated by individuals with 
current experience of those states. METHODS: EQ-5D data from several different UK 
sources were pooled yielding a total of 23,679 useable observations. The health state 
deﬁned by each respondent’s self-rated problem level on the 5 EQ-5D dimensions was 
determined, yielding a total of 139 unique EQ-5D health states. The mean VAS rating 
was computed for each of these states. 0/1 dummy variables were deﬁned for each of 
the EQ-5D dimensions and an OLS regression analysis was performed with the mean 
self-rated VAS rating as the dependent variable. RESULTS: The model ﬁtted the mean 
VAS ratings data very well (r2 = 0.985) when forced through the origin. All decrements 
within dimension were monotonic and internally consistent. Residuals were 5 points 
or lower when observed and estimated values were compared. Estimated values for 
all EQ-5D health states were computed so that full health (11111) has a value of 100 
and worst possible health (33333) has a value of 0. CONCLUSIONS: This methodol-
ogy contrasts markedly with the more complex requirements of utility estimation and 
produces a weighting system that can be used to meaningfully report health status. It 
has applicability as a performance measurement tool with real-world interpretability. 
If corresponding data from other countries were included then a single global scoring 
system for EQ-5D could be established.
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OBJECTIVES: To test whether social preferences for allocating health resources are 
affected by the framing of questions METHODS: 162 students from the University 
of Southern California were asked four questions. Each question asked participants 
to select one of two possible treatments with each treatment resulting in a different 
distribution of outcomes for the treated population. After treatment, patients could 
have one of three outcomes: “Good Health”, “Poor Health”, or “Death.” The ﬁrst 
medication listed always had 19 fewer people in “Good Health”, 23 more people in 
“Poor Health” and 4 fewer people in the “Death” state relative to the second medica-
tion listed. The only aspect that varied between questions was the number of patients 
unaffected by treatment choice. Two questions had a “standard frame”, indicative of 
commonly asked questions in the equity literature. The remaining two questions had 
a “sure thing” frame, in which common outcomes between the two treatments were 
made apparent. Frame order was randomized for each of the participants. A key 
qualitative principle behind QALY maximization is that those individuals unaffected 
by a policy choice should not inﬂuence the policy choice. Violations of this principle 
were measured for each of the frames. RESULTS: The proportion of violations of 
QALY maximization (indicated by switched preference) in the “standard” frame was 
0.31 (56/183); while in the “sure-thing” frame, the proportion was 0.08 (15/183). 
The difference between groups was statistically signiﬁcant (p < 0.001) CONCLU-
SIONS: The most common way of asking for preferences for equality tends to foster 
aversion to inequality, which does not support QALY maximization. In contrast, a 
frame that separates common outcomes between choices may occasion preferences 
that maximize QALYs. These results have implications for measurement techniques 
such as the person tradeoff which assumes framing has no effect on preferences for 
health allocation.
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OBJECTIVES: Recognizing that medication non-adherence is a signiﬁcant cause of 
suboptimal health outcomes, the objective of this study was to obtain patient feedback 
on communication with providers and preferences for various adherence tools. 
METHODS: Online cross-sectional survey of patients with: asthma/COPD, allergies, 
bipolar disease, cardiovascular disease, depression, diabetes, multiple sclerosis, osteo-
porosis, pain syndromes, and rheumatoid arthritis. Patients completed close-ended 
questions about the amount of information they received from health care providers; 
the usefulness of various adherence tools in managing their condition; and the impact 
of additional disease/product information. Patient ratings of each adherence tool were 
scored on a scale ranging from 0 (“not at all valuable”) to 3 (“very valuable”). Paired 
t-test was used to compare the preference for explicit adherence reminders (medication 
reminders via email, telephone and SMS text) versus each of the other adherence tools. 
The association of patient preferences for each tool with age was evaluated using 
Pearson correlation coefﬁcients and using one-way analysis of variance (ANOVA) for 
associations with medical conditions, gender, education, family income and health 
insurance source. RESULTS: A total of 642 patients completed the survey. Forty 
percent reported receiving inadequate information from their physician (range: 22% 
for rheumatoid arthritis to 54% for cardiovascular disease). Across medical conditions 
groups, patients preferred adherence tools that conveyed information about medica-
tion dosing, safety, and drug interactions. Explicit adherence reminders were uni-
formly deemed least valuable compared to other adherence tools (all p-values < 0.0001 
based on paired t-tests). There were some differences observed in preferences for 
adherence tools across condition, gender, and age; no signiﬁcant associations were 
found between patient preferences and education level, family income, or source of 
health insurance. CONCLUSIONS: Patients often receive inadequate information 
about their medications and conditions. Medication adherence tools that educate 
patients may simultaneously address their desire for more information and reinforce 
adherence.
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OBJECTIVES: To document the extent to which treatment satisfaction evidence is 
provided in support of EMEA regulatory approvals and to evaluate the quality of 
evidence provided in support of treatment satisfaction claims.METHODS: A review 
of EMEA published reports for all drugs approved since a centralised process was 
established in 1995 was undertaken: speciﬁcally the Scientiﬁc Discussion/Public 
Assessment Reports were reviewed for evaluations of patient-reported treatment sat-
isfaction. The wording and types of PROs contained within approved product labels 
were examined in order to establish the nature and extent of previous successful claims 
for treatment satisfaction.RESULTS: A total of 508 currently authorised medicinal 
product approvals were reviewed, 26 made reference to ‘satisfaction’ or ‘satisﬁed’ but 
9 were excluded for not focusing on patient-reported treatment satisfaction thus 17 
medicinal products were identiﬁed as having a direct reference to evaluating patient-
reported treatment satisfaction. These 17 approvals ranged from July 1998 to July 
2008, and were distributed across a broad range of pharmaco-therapeutic groups with 
a cluster of approvals for ‘insulin analogues for injection, long lasting’ (n = 4): 10/17 
approvals provided limited reference to the way in which treatment satisfaction was 
evaluated e.g. reference to a total satisfaction score without any further details, 2/17 
measured treatment satisfaction using a VAS; 5/17 referenced a speciﬁc treatment 
satisfaction measure. 5/17 provided treatment satisfaction of results, yet only two of 
these gave any details on the way in which treatment satisfaction was measured. 
